Evidence map›Paper›PMID 27578439›Full record

ReviewAnnual review of virology2016

Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

M L Boisen, J N Hartnett, A Goba, M A Vandi, D S Grant, J S Schieffelin, R F Garry, L M Branco

Abstract readReview
In one paragraph

Review in Annual review of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Ebola Virus IgG Seroprevalence in Southern Mali.Emerging infectious diseases · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Analysis of CD8Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  13. Article
  14. Article
  15. Flex-nucleoside analogues - Novel therapeutics against filoviruses.Bioorganic & medicinal chemistry letters · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M L BoisenCorgenix Inc., Broomfield, Colorado 80020.
J N HartnettDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana 70112; email: rfgarry@tulane.edu.
A GobaLassa Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
M A VandiLassa Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
D S GrantLassa Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
J S SchieffelinSection of Infectious Diseases, Department of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana 70112.
R F GarryDepartment of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana 70112; email: rfgarry@tulane.edu.
L M BrancoZalgen Labs, LLC, Germantown, Maryland 20876; email: lbranco@zalgenlabs.com.

Funding

Tulane Building Interdisciplinary Research Careers in Women's Health (BIRCWH)K12HD043451 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KROUSEL-WOOD, MARIE · 2002 to 2023
$9.9M
Recombinant antigen diagnostics for filovirusesR44AI088843 · NIAID · ZALGEN LABS, LLC · PI BOISEN, MATTHEW L · 2014 to 2016
$3.0M
NIAID NIH HHS R44 AI088843NICHD NIH HHS K12 HD043451
6 · The paper itself

Abstract

The 2013-16 West African Ebola outbreak is the largest, most geographically dispersed, and deadliest on record, with 28,616 suspected cases and 11,310 deaths recorded to date in Guinea, Liberia, and Sierra Leone. We provide a review of the epidemiology and management of the 2013-16 Ebola outbreak in West Africa aimed at stimulating reflection on lessons learned that may improve the response to the next international health crisis caused by a pathogen that emerges in a region of the world with a severely limited health care infrastructure. Surveillance efforts employing rapid and effective point-of-care diagnostics designed for environments that lack advanced laboratory infrastructure will greatly aid in early detection and containment efforts during future outbreaks. Introduction of effective therapeutics and vaccines against Ebola into the public health system and the biodefense armamentarium is of the highest priority if future outbreaks are to be adequately managed and contained in a timely manner.

Indexed as

Disease ManagementAdultAfrica, WesternDisease OutbreaksEbola VaccinesEbolavirusFemaleHemorrhagic Fever, EbolaHumansMaleMiddle AgedPoint-of-Care SystemsPopulation SurveillancePublic HealthEbola VaccinesEbola virusepidemiologyfilovirusesoutbreak managementpoint-of-care testingviral diagnosticsviral geneticsviral therapeuticsviral vaccines

Identifiers

PMID27578439
PMCPMC7297506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.